Abstract
Important advances in fibroblastic and fibrohistiocytic tumors relevant to dermatologists and dermatopathologists include (1) recognition that myxofibrosarcoma is a distinct entity that frequently arises in skin; (2) CD10 is sensitive but not specific atypical fibroxanthoma; (3) neurothekeomas lacking S100 expression are probably fibrohistiocytic/fibroblastic tumors, whereas S100+ myxoid variants are better classified as nerve sheath myxomas; (4) the recognition of a primary cutaneous variant of solitary fibrous tumor; (5) thelimitations of b-catenin immunohistochemistry in desmoid tumors; and (6) the prognostic utility of clinical and histopathologic variables in dermatofibrosarcoma protuberans, and the effects of imatinib mesylate therapy.
Copyright © 2012. Published by Elsevier Inc.
MeSH terms
-
Antigens, CD34 / metabolism
-
Antineoplastic Agents / therapeutic use
-
Benzamides
-
Dermatofibrosarcoma / drug therapy
-
Dermatofibrosarcoma / metabolism
-
Dermatofibrosarcoma / secondary
-
Fibromatosis, Abdominal / metabolism
-
Histiocytoma, Malignant Fibrous / pathology*
-
Humans
-
Imatinib Mesylate
-
Myxosarcoma / pathology*
-
Neprilysin / metabolism
-
Neurothekeoma / pathology*
-
Oncogene Proteins, Fusion / metabolism
-
Piperazines / therapeutic use
-
Prognosis
-
Pyrimidines / therapeutic use
-
Skin Neoplasms / metabolism
-
Skin Neoplasms / pathology*
-
Solitary Fibrous Tumors / metabolism
-
Solitary Fibrous Tumors / pathology
-
beta Catenin / metabolism
Substances
-
Antigens, CD34
-
Antineoplastic Agents
-
Benzamides
-
COLIA1-PDGFB fusion protein, human
-
Oncogene Proteins, Fusion
-
Piperazines
-
Pyrimidines
-
beta Catenin
-
Imatinib Mesylate
-
Neprilysin